These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23784442)

  • 1. Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice.
    Vasu S; Moffett RC; McCluskey JT; Hamid MH; Irwin N; Flatt PR
    Gene Ther; 2013 Nov; 20(11):1077-84. PubMed ID: 23784442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS; Srinivasan BP; Gandhi S
    J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.
    Shao W; Wang Z; Ip W; Chiang YT; Xiong X; Chai T; Xu C; Wang Q; Jin T
    Am J Physiol Endocrinol Metab; 2013 Jun; 304(12):E1263-72. PubMed ID: 23571712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.
    Riedel MJ; Gaddy DF; Asadi A; Robbins PD; Kieffer TJ
    Gene Ther; 2010 Feb; 17(2):171-80. PubMed ID: 19865180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged remission of diabetes by regeneration of beta cells in diabetic mice treated with recombinant adenoviral vector expressing glucagon-like peptide-1.
    Liu MJ; Shin S; Li N; Shigihara T; Lee YS; Yoon JW; Jun HS
    Mol Ther; 2007 Jan; 15(1):86-93. PubMed ID: 17164779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cycloart-23-ene-3β, 25-diol stimulates GLP-1 (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats: a mechanistic approach.
    Badole SL; Mahamuni SP; Bagul PP; Khose RD; Joshi AC; Ghule AE; Bodhankar SL; Raut CG; Khedkar VM; Coutinho EC; Wagh NK
    Eur J Pharmacol; 2013 Jan; 698(1-3):470-9. PubMed ID: 23117087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice.
    Irwin N; McClean PL; Harriott P; Flatt PR
    Exp Gerontol; 2007 Apr; 42(4):296-300. PubMed ID: 17184947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
    Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
    Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes.
    Soltani N; Kumar M; Glinka Y; Prud'homme GJ; Wang Q
    Gene Ther; 2007 Jun; 14(12):981-8. PubMed ID: 17410180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.
    Irwin N; Pathak V; Pathak NM; Gault VA; Flatt PR
    Diabetes Obes Metab; 2015 Sep; 17(9):887-95. PubMed ID: 26095087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes.
    Steenberg VR; Jensen SM; Pedersen J; Madsen AN; Windeløv JA; Holst B; Quistorff B; Poulsen SS; Holst JJ
    Diabetologia; 2016 Feb; 59(2):363-70. PubMed ID: 26537124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huang-lian-jie-du-decoction modulates glucagon-like peptide-1 secretion in diabetic rats.
    Yu YL; Lu SS; Yu S; Liu YC; Wang P; Xie L; Wang GJ; Liu XD
    J Ethnopharmacol; 2009 Jul; 124(3):444-9. PubMed ID: 19497359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.
    Merani S; Truong W; Emamaullee JA; Toso C; Knudsen LB; Shapiro AM
    Endocrinology; 2008 Sep; 149(9):4322-8. PubMed ID: 18511515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
    Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
    Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
    Kim YS; Oh SH; Park KS; No H; Oh BJ; Kim SK; Jung HS; Kim JH; Lee MS; Lee MK; Kim KW
    Pancreas; 2011 Aug; 40(6):855-60. PubMed ID: 21747318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis.
    Toyoda K; Okitsu T; Yamane S; Uonaga T; Liu X; Harada N; Uemoto S; Seino Y; Inagaki N
    Biochem Biophys Res Commun; 2008 Mar; 367(4):793-8. PubMed ID: 18211828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin.
    Gao M; Tong Y; Li W; Gao X; Yao W
    Artif Cells Nanomed Biotechnol; 2013 Jun; 41(3):159-64. PubMed ID: 22889326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionality and antidiabetic utility of β- and L-cell containing pseudoislets.
    Green AD; Vasu S; Flatt PR
    Exp Cell Res; 2016 Jun; 344(2):201-9. PubMed ID: 27068377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.